Inaxaplin's Phase 2b Signal Is Real But Uncontrolled — AMPLITUDE Is the Only Verdict That Matters

Vertex's Inaxaplin Shows Positive Phase 2b Results in AMKD

Vertex Pharmaceuticals announced positive results from the Phase 2b AMPLIFIED study of inaxaplin for APOL1-mediated kidney disease (AMKD) in two additional patient populations. In people with AMKD and modest proteinuria (N=23), inaxaplin led to a -42.7% reduction in urine albumin to creatinine ratio (UACR) at Week 13. For those with AMKD and type 2 diabetes (N=18), UACR decreased by -17.3% over the same period. The drug was generally safe and well-tolerated across both cohorts. Additionally, Vertex confirmed the completion of enrollment for its pivotal Phase 2/3 AMPLITUDE trial, with interim analysis results anticipated in early 2027. Positive data from AMPLITUDE could potentially support an accelerated approval pathway in the U.S.

• The Phase 2b AMPLIFIED study demonstrated significant efficacy for inaxaplin in people with AMKD and modest proteinuria (UACR ≥0.1 g/g to <0.42 g/g). Treatment resulted in a -42.7% reduction in UACR and a -44.7% reduction in UPCR at Week 13 compared to baseline. These results are consistent with previous Phase 2a findings in AMKD with FSGS, reinforcing inaxaplin's potential as a first-in-class treatment for the underlying cause of AMKD.
• In the cohort of AMKD patients with type 2 diabetes, inaxaplin led to a -17.3% reduction in UACR and a -25.4% reduction in UPCR at Week 13. While smaller in magnitude, this effect is still considered positive. Across both cohorts, inaxaplin exhibited a favorable safety profile, being generally safe and well-tolerated with no serious adverse events related to the drug and most AEs being mild or moderate, with headache being the most common.
• Vertex has successfully completed full enrollment in the pivotal Phase 2/3 AMPLITUDE study, which evaluates inaxaplin in people with severe proteinuria and no other kidney disease-causing comorbidities. The company remains on track to release data from the pre-planned interim analysis in early 2027, after the cohort reaches 48 weeks of treatment. Positive interim data could potentially serve as the basis for accelerated approval of inaxaplin in the United States.

Inaxaplin's Positive Phase 2b Results in AMKD Populations

Two phase 1 studies evaluated the safety, tolerability, and pharmacokinetics of inaxaplin — an inhibitor of APOL1 channel activity — in healthy adults, using single-ascending dose (SAD) and multiple-ascending dose (MAD) designs. In the SAD cohorts, participants received inaxaplin as a single dose ranging from 7.5 mg to 165 mg or placebo. In the MAD cohorts, participants received multiple doses ranging from 15 to 120 mg daily or placebo for 14 days. A total of 178 participants were randomized across both studies (mean age: 36.7 years; 94.9% male).

Inaxaplin demonstrated a favorable safety and tolerability profile across both study designs. The proportion of participants reporting any adverse events (AEs) was similar between the inaxaplin (24.6%) and placebo (22.7%) groups, with all AEs classified as mild or moderate in severity. No serious AEs were reported, and there were no drug-related treatment discontinuations. Headache was the most common AE, occurring in 10.4% of inaxaplin-treated participants versus 2.3% in the placebo group. No clinically relevant trends were observed in laboratory values, electrocardiograms (ECGs), or vital signs.

These findings establish that inaxaplin is safe and well tolerated at single doses up to 165 mg and multiple doses up to 120 mg daily for 14 days. The results are described as consistent with the favorable safety profile observed in a completed phase 2a proof-of-concept study, which also demonstrated that inaxaplin reduces proteinuria in patients with APOL1-mediated kidney disease (AMKD). Collectively, these data are cited as supporting continued evaluation of inaxaplin in an ongoing phase 2/3 pivotal trial as a potential precision medicine for patients with AMKD.

Unpacking the AMPLIFIED Study Design and Key Findings

Two key programs have advanced the clinical evaluation of APOL1-mediated kidney disease (AMKD): phase 1 studies characterizing the safety and pharmacokinetics of inaxaplin, an APOL1 channel activity inhibitor, and a population-based cohort study examining APOL1 high-risk genotype distribution and early renal function change. Together, these efforts establish the foundational evidence base informing ongoing pivotal development.

Addressing the Significant Unmet Need in AMKD Treatment

Treatment of APOL1-mediated kidney disease (AMKD) remains constrained by an incomplete understanding of disease mechanisms and the absence of genotype-tailored therapeutic strategies. The interplay of genetic risk, environmental triggers, and metabolic dysregulation creates a complex pathophysiological landscape that current standard-of-care approaches address only partially.

• Mechanistic heterogeneity limits targeted intervention. APOL1 risk variants (G1 and G2) drive podocyte injury through multiple, partially distinct pathways — including enhanced lysosomal membrane permeability, endoplasmic reticulum stress with downstream loss of nephrin and podocin protein expression, and perturbation of purine metabolism leading to ATP depletion. No single therapeutic mechanism addresses all of these simultaneously, and the mechanisms underlying nephropathy caused by APOL1 risk variant genotypes are described as "not fully understood."

• Differential genotype responsiveness to ACE inhibition. In APOL1 BAC-transgenic mouse models, standard-dose lisinopril reduced proteinuria by approximately 90-fold and reduced glomerulosclerosis in G1/G1 mice, with effects independent of blood pressure. However, G2/G2 mice required lisinopril doses two times higher than were effective in G1/G1 mice and achieved a much smaller benefit. Dapagliflozin did not alter disease progression in either G1/G1 or G2/G2 mice, and it remains to be determined if similar differences in ACE inhibitor responsiveness are observed in patients.

• Amplification of injury by adverse host factors. Adverse host factors — including hydrogen peroxide, hypoxia, TNF-α, puromycin aminonucleoside, and HIV infection — augment APOL1 and APOL1 variant-induced podocyte injury, with HIV infection described as especially prominent. Vascular smooth muscle cells further serve as an endocrine/paracrine source of APOL1 variants, contributing to podocyte injury in an HIV milieu. Current treatment frameworks do not systematically account for these compounding environmental and systemic triggers.

• Metabolic dysregulation as an underexplored therapeutic target. Expression of APOL1 G2/G2 downregulates the rate-limiting enzymes of purine biosynthesis and induces ATP depletion. Supplementation with the purine biosynthesis precursor AICAr rescued purine biosynthesis, reduced cytotoxicity, boosted ATP in cell models, and reduced albuminuria in interferon-γ treated G2/G2 transgenic mice — yet metabolic intervention remains outside current standard-of-care approaches for AMKD.

Inaxaplin's Broad Potential in Genetically Driven Kidney Disease

The recent positive Phase 2b data for inaxaplin marks a pivotal moment in the development of targeted therapies for APOL1-mediated kidney disease (AMKD). This genetically defined condition, driven by specific APOL1 variants, currently lacks disease-modifying treatments, leaving patients vulnerable to progressive kidney function decline. Inaxaplin's mechanism as an APOL1 channel inhibitor directly addresses the root cause, representing a significant step forward in precision nephrology.

The observed reductions in urine albumin to creatinine ratio (UACR) across different AMKD patient cohorts are particularly encouraging. A -42.7% reduction in those with modest proteinuria and a -17.3% reduction in patients with type 2 diabetes, alongside a favorable safety profile, suggest broad applicability. This expansion of the potential patient population beyond the initial focal segmental glomerulosclerosis (FSGS) indication underscores the drug's versatility and market potential. The completion of enrollment for the pivotal Phase 2/3 AMPLITUDE trial, with interim results anticipated in early 2027, sets the stage for a potential accelerated approval pathway.

However, several considerations remain. While UACR reduction is a strong surrogate, the ultimate clinical benefit in terms of preserving kidney function and delaying end-stage kidney disease will need confirmation from the larger, longer-term AMPLITUDE study. The relatively small size of the Phase 2b cohorts also means that the efficacy observed in these specific subgroups will require further validation. Nevertheless, the consistent safety profile across studies, from healthy volunteers to AMKD patients, provides a solid foundation. This development positions inaxaplin as a potential first-in-class therapy that could redefine the treatment landscape for AMKD, offering a much-needed therapeutic option for a patient population with high unmet needs.